Berlin-chemie Ag

Menarini Ricerche S.p.a.

Mario Bigioni

Giuseppe Merlino

Monica Binaschi

Andrea Pellacani

Francesco Bertoni

Cecilia Simonelli

Carlo Alberto Maggi

Fabio Animati

Amalia Cipollone

Marco Berettoni

The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.

Pharmaceutical combinations comprising an anti-LY75 antibody

The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) Venetoclax; methods for preparing pharmaceutical combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.

Pharmaceutical combinations

The present invention refers to compounds of general formula (I), the pharmaceutically acceptable salts thereof, the processes for their preparation, and the pharmaceutical compositions containing them.

L-arabino-disaccharides of anthracyclines, processes for their preparation, and pharmaceutical compositions containing them

Growing community of inventors

Rome, Italy

Mario Bigioni